Dupuytren's Disease Therapeutics Market Segmentation:
Type, (I, II, III)
The Type II segment is anticipated to dominate dupuytren’s disease therapeutics market share of around 52% by the end of 2035. Type II is dominating as most of Dupuytren's patients are affected by this condition. Furthermore, the growth is accelerated by the effective management of mid-stage symptoms with targeted therapeutics before severe contracture occurs. In July 2022, a study on combining aponeurotomy with adipose tissue grafting to reduce recurrence rates highlighted demand in this segment, as treatments for Type II cases are essential in minimizing disease progression. Furthermore, ongoing research initiatives continue to improve mid-stage intervention strategies, solidifying Type II’s market dominance.
Therapeutics (Collagenase Injection, Steroids, Immune-modulators)
In dupuytren’s disease therapeutics market, collagenase injection segment is set to hold revenue share of more than 54.2% by 2035 due to its non-invasive method and high patient compliance rates. Collagenase injections break down collagen build-up in affected areas, making the treatment effective without surgery. In February 2023, Endo's ‘Man with a Plan’ campaign emphasized awareness of collagenase treatments for related conditions, noting that this segment of non-invasive Dupuytren's treatment plays a vital role. With a strong preference for non-invasive treatments, collagenase injections continue to gain widespread acceptance, making them an important segment of dupuytren's disease therapeutics market.
Our in-depth analysis of the dupuytren’s disease therapeutics market includes the following segments:
|
Type |
|
|
Therapeutics |
|
|
Distribution Channel |
|
